Switch theme
Sign up to access all valuation multiples
Synmosa Biopharma Corp is engaged in the research and development, manufacturing, marketing, and distribution of pharmaceutical products, medical devices, cosmetics, animal drugs, chemical food additives, and beverages. It is also involved in manufacturing and sales, and environmental drugs wholesale (retail), as well as the import and export of related businesses. The company provides prescription, OTC medicines, and healthcare products under its Synmosa trademark. The reporting segments of the company are; the Generic Drugs segment which derives key revenue, and the Active Pharmaceutical Ingredients segment.
1970
457
LTM Revenue n/a
LTM EBITDA n/a
$493M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Synmosa Biopharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Synmosa Biopharma achieved revenue of $168M and an EBITDA of $32.0M.
Synmosa Biopharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Synmosa Biopharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $155M | $168M | XXX | XXX | XXX |
| Gross Profit | $55.2M | $64.0M | XXX | XXX | XXX |
| Gross Margin | 36% | 38% | XXX | XXX | XXX |
| EBITDA | $30.5M | $32.0M | XXX | XXX | XXX |
| EBITDA Margin | 20% | 19% | XXX | XXX | XXX |
| Net Profit | $24.1M | $18.0M | XXX | XXX | XXX |
| Net Margin | 16% | 11% | XXX | XXX | XXX |
| Net Debt | $67.0M | $43.5M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Synmosa Biopharma's stock price is TWD 31 (or $1).
Synmosa Biopharma has current market cap of TWD 15.7B (or $473M), and EV of TWD 16.3B (or $493M).
See Synmosa Biopharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $493M | $473M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Synmosa Biopharma has market cap of $473M and EV of $493M.
Synmosa Biopharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Synmosa Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Synmosa Biopharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $493M | XXX | XXX | XXX |
| EV/Revenue | 2.9x | XXX | XXX | XXX |
| EV/EBITDA | 15.4x | XXX | XXX | XXX |
| P/E | 22.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 31.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpSynmosa Biopharma's NTM/LTM revenue growth is n/a
Synmosa Biopharma's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Synmosa Biopharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Synmosa Biopharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Synmosa Biopharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 8% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 19% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 18% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 30% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Synmosa Biopharma acquired XXX companies to date.
Last acquisition by Synmosa Biopharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Synmosa Biopharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Synmosa Biopharma founded? | Synmosa Biopharma was founded in 1970. |
| Where is Synmosa Biopharma headquartered? | Synmosa Biopharma is headquartered in Taiwan. |
| How many employees does Synmosa Biopharma have? | As of today, Synmosa Biopharma has 457 employees. |
| Is Synmosa Biopharma publicy listed? | Yes, Synmosa Biopharma is a public company listed on ROCO. |
| What is the stock symbol of Synmosa Biopharma? | Synmosa Biopharma trades under 4114 ticker. |
| When did Synmosa Biopharma go public? | Synmosa Biopharma went public in 2003. |
| Who are competitors of Synmosa Biopharma? | Similar companies to Synmosa Biopharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Synmosa Biopharma? | Synmosa Biopharma's current market cap is $473M |
| What is the current revenue growth of Synmosa Biopharma? | Synmosa Biopharma revenue growth between 2023 and 2024 was 8%. |
| Is Synmosa Biopharma profitable? | Yes, Synmosa Biopharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
